GR890100631A - The receptor binding region of ebvgp 350 - Google Patents

The receptor binding region of ebvgp 350

Info

Publication number
GR890100631A
GR890100631A GR890100631A GR890100631A GR890100631A GR 890100631 A GR890100631 A GR 890100631A GR 890100631 A GR890100631 A GR 890100631A GR 890100631 A GR890100631 A GR 890100631A GR 890100631 A GR890100631 A GR 890100631A
Authority
GR
Greece
Prior art keywords
ebv
chemical formula
ebvgp
receptor binding
binding region
Prior art date
Application number
GR890100631A
Other languages
Greek (el)
Inventor
Nemerow R Glen
Cooper R Neil
Original Assignee
Scripps Clinic Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res
Publication of GR890100631A publication Critical patent/GR890100631A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Περιγράφονται πολυπεπτίδια αντιδρώντα μετά της (χημικός τύπος) αντιστοιχούντα εις τας ρίζας αμινοξέων της περιοχής του αμινικού άκρου της EBV gp350/220 ως και ανάλογα αυτών. Αλληλουχίαι πολυπετιδίων αντιστοιχούσαι εις 5 τουλάχιστον διαδοχικάς ρίζας της γραμμικής αλληλουχίας της gp350/220 του EBV και περιέχουσαι μίαν τουλάχιστον των ριζών 21-24 ή 25-27 της γραμμικής αλληλουχίας, δεσμεύονται προς τον υποδοχέα (χημικός τύπος). Συσσωματώματα πολυπεπτιδίων αποτελούμενα εκ δύο τουλάχιστον μετά της (χημικός τύπος) αντιδρώντων πολυπεπτιδίων ευρίσκουν χρήσιν ως ενισχυταί των ανοσοποιήσεων διεγείροντα τα κύτταρα Β. Τα συσσωματώματα παρεμποδίζον επίσης την μόλυνσιν των κυττάρων Β υπό του EBV. Περγράφονται επίσης μέθοδοι θεραπείας και διαγνώσεως. ωPost-reactive polypeptides (chemical formula) corresponding to the amino acid residues of the amino terminal region of EBV gp350/220 and analogs thereof are described. Polypeptide sequences corresponding to at least 5 consecutive residues of the linear sequence of gp350/220 of EBV and containing at least one of residues 21-24 or 25-27 of the linear sequence bind to the receptor (chemical formula). Polypeptide aggregates consisting of at least two post (chemical formula) reactive polypeptides find use as boosters of immunizations by stimulating B cells. Aggregates also prevent B cell infection by EBV. Methods of treatment and diagnosis are also described. oh

GR890100631A 1988-10-03 1989-10-03 The receptor binding region of ebvgp 350 GR890100631A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25320588A 1988-10-03 1988-10-03

Publications (1)

Publication Number Publication Date
GR890100631A true GR890100631A (en) 1990-11-29

Family

ID=22959318

Family Applications (1)

Application Number Title Priority Date Filing Date
GR890100631A GR890100631A (en) 1988-10-03 1989-10-03 The receptor binding region of ebvgp 350

Country Status (5)

Country Link
EP (1) EP0436626A1 (en)
AU (1) AU4341189A (en)
GR (1) GR890100631A (en)
PT (1) PT91877A (en)
WO (1) WO1990004176A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
ATE161966T1 (en) * 1990-06-29 1998-01-15 Du Pont TEST FOR DETECTING AND/OR QUANTIFYING AN ANTIBODY RESPONSE OF A MAMMAL TO EPSTEIN-BARR VIRUS MEMBRANE ANTIGEN
AU710369B2 (en) * 1994-10-25 1999-09-16 Glaxo Group Limited Binding agents for treatment of inflammatory, autoimmune or allergic diseases
ZA972087B (en) * 1996-03-15 1997-10-24 Theratech Inc Targeting macromolecular produgs to T lymphocytes.
AU762799B2 (en) * 1998-06-12 2003-07-03 Henry M. Jackson Foundation For The Advancement Of Military Medicine Enhancement of B cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and EBV Gp350/220
EP1229043A1 (en) 2001-01-30 2002-08-07 Cyto-Barr B.V. Peptides derived from Epstein Barr virus (EBV) proteins LMP1, LMP2 and BARF1 antibody reagents reactive therewith
FR2850384A1 (en) 2003-01-28 2004-07-30 Centre Nat Rech Scient New antigen from intracellular pathogens, useful in vaccines against bacterial and viral infections, comprises sequences from extracellular domains of type III membrane proteins, also derived antibodies
WO2010033868A2 (en) * 2008-09-19 2010-03-25 Taligen Therapeutics, Inc. Ligand-specific non-antibody compounds that inhibit cr2 activation and methods of use thereof
CN104168918A (en) 2012-03-19 2014-11-26 德国癌症研究中心 B-cell receptor complex binding proteins containing T-cell epitopes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0151079A2 (en) * 1984-01-30 1985-08-07 University Of Chicago Vaccine against epstein-barr virus
EP0173254A1 (en) * 1984-08-23 1986-03-05 Hans Joachim Wolf DNA sequences of the EBV genome, recombinant DNA molecules, processes for producing EBV-related antigens, diagnostic compositions and pharmaceutical compositions containing said antigens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654419A (en) * 1984-08-08 1987-03-31 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to epstein-barr virus nuclear antigen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0151079A2 (en) * 1984-01-30 1985-08-07 University Of Chicago Vaccine against epstein-barr virus
EP0173254A1 (en) * 1984-08-23 1986-03-05 Hans Joachim Wolf DNA sequences of the EBV genome, recombinant DNA molecules, processes for producing EBV-related antigens, diagnostic compositions and pharmaceutical compositions containing said antigens

Also Published As

Publication number Publication date
EP0436626A1 (en) 1991-07-17
PT91877A (en) 1990-04-30
WO1990004176A1 (en) 1990-04-19
AU4341189A (en) 1990-05-01

Similar Documents

Publication Publication Date Title
DE3676670D1 (en) SOLUBILIZATION OF PROTEINS FOR PHARMACEUTICAL COMPOSITIONS BY POLYMER CONJUGATION.
PT86465A (en) Process for the preparation of novel peptides having an amino acid sequence as derived from the amino acid sequence of the human granulocyte colony stimulating factor (hg-csf)polypeptide
HUT38125A (en) Process for preparing lymphokines /cytotoxic factors/ and pharmaceutical compositions containing such active substance
MY101887A (en) A novel human physiologically active polypeptide.
ATE192500T1 (en) RECOMBINANT VIRUS VECTORS FOR EXPRESSION IN MUSCLE CELLS
GR890100631A (en) The receptor binding region of ebvgp 350
CA2312004A1 (en) Site-specific preparation of polyethylene glycol-grf conjugates
BR9915542A (en) Beta-1a interferon polymer conjugates and uses
NO852872L (en) PROCEDURE FOR THE PREPARATION OF NEW TETRAPYROLS.
ES2009238A6 (en) Mycobacterial recombinants and peptides
DE3854952D1 (en) MYCOBACTERIAL RECOMBINANTS AND PEPTIDES
EP0372752A3 (en) Cd4 polypeptide derivatives
DK193887A (en) PEPTID WITH BRONCHODIL ARTS AND HYPOTENSIVE ACTIVITY
DK491487A (en) DNA SEQUENCE FOR EXPRESSION OF BIOLOGICAL ACTIVE FACTOR XIII AND USE OF SAME
JPS5692850A (en) Acylpeptide* its manufacture and medicinal medicine containing it
MY102167A (en) Bactericidal formulations for use in the area of veterinary medicine.
IL74947A (en) Analogs of human gamma interferon having the partial sequence of human gamma interferon and genetic engineering process for the preparation thereof
ES2012129A6 (en) Soluble human cd4 fragments and uses therefor.
GR3020060T3 (en) Modified proteins, modified interferons, alphas and beta, phosphorylated proteins and analogues, DNA sequences, applications and uses thereof
DE68926679D1 (en) PHYSIOLOGICALLY ACTIVE POLYPEPTIDE, RECOMBINANT PLASMIDE, RECOMBINANT MICROBIAL CELLS, MEDICAL PREPARATION AND METHOD FOR OBTAINING THE PURIFIED POLYPEPTIDE
NO904251L (en) PROCEDURE FOR PREPARING AN APPROXIMATELY PURE POLYPEPTIME.
EP0110791A3 (en) Peptides containing an immunogenic site of the poliovirus, and dna's containing nucleotide fragments encoding for these peptides
ES2058992T3 (en) A PROCEDURE FOR THE PREPARATION OF POLYPEPTIDE THAT STIMULATES T CELLS.
NO873437L (en) HUMAN PLACENTA ANGIOGEN FACTOR FOR AA STIMULATED CAPILLA ENDOTEL CELL PROTEASE SYNTHESIS, DNA SYNTHESIS AND MIGRATION.
IL48352A (en) 4-o-(2',6-diamino-2',3-,6'-tridesoxy a-dribohexopyranosyl)-6-o-(3''-methyl amino-3'',4'',6''-tridesoxy- ,d-xylohexopyranosyl)-2-desoxystreptamine and its salts,process for por preparing them and pharmaceutical compositions containing them